195 related articles for article (PubMed ID: 30181190)
41. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Vicus D; Finch A; Cass I; Rosen B; Murphy J; Fan I; Royer R; McLaughlin J; Karlan B; Narod SA
Gynecol Oncol; 2010 Sep; 118(3):299-302. PubMed ID: 20570322
[TBL] [Abstract][Full Text] [Related]
43. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
44. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Leeper K; Garcia R; Swisher E; Goff B; Greer B; Paley P
Gynecol Oncol; 2002 Oct; 87(1):52-6. PubMed ID: 12468342
[TBL] [Abstract][Full Text] [Related]
45. Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
Zidekova D; Waczulikova I; Dolesova L; Vavrova L; Hamidova O; Lohajova Behulova R; Konecny M
Neoplasma; 2018; 65(2):309-315. PubMed ID: 29534594
[TBL] [Abstract][Full Text] [Related]
46. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
[TBL] [Abstract][Full Text] [Related]
47. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
[TBL] [Abstract][Full Text] [Related]
48. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
49. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
50. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
[TBL] [Abstract][Full Text] [Related]
52. Evaluating the NCCN Clinical Criteria for Recommending
Cropper C; Woodson A; Arun B; Barcenas C; Litton J; Noblin S; Liu D; Park M; Daniels M
J Natl Compr Canc Netw; 2017 Jun; 15(6):797-803. PubMed ID: 28596260
[No Abstract] [Full Text] [Related]
53. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
54. Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
Lovejoy LA; Turner CE; Shriver CD; Ellsworth RE
Mil Med; 2021 Jul; 186(7-8):e737-e742. PubMed ID: 33206196
[TBL] [Abstract][Full Text] [Related]
55. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
[TBL] [Abstract][Full Text] [Related]
56. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
57. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
[TBL] [Abstract][Full Text] [Related]
58. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
Metcalfe KA; Mian N; Enmore M; Poll A; Llacuachaqui M; Nanda S; Sun P; Hughes KS; Narod SA
Breast Cancer Res Treat; 2012 Jun; 133(2):735-40. PubMed ID: 22240989
[TBL] [Abstract][Full Text] [Related]
60. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
